Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2020’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

– The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Agios Pharmaceuticals Inc

Arromax Pharmatech Co Ltd

Ascentage Pharma Group International

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

AUM Biosciences Pte Ltd

Bio-Path Holdings Inc

BioLineRx Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celularity Inc

Escend Pharmaceuticals Inc

Eureka Therapeutics Inc

ExCellThera Inc

Fate Therapeutics Inc

Fusion Pharma LLC

Gamida Cell Ltd

GlaxoSmithKline Plc

GlycoMimetics Inc

GT Biopharma Inc

Handa Pharmaceuticals LLC

Hebei Senlang Biotechnology Inc Ltd

HEC Pharm Co Ltd

Helocyte Biosciences Inc

HighPass Bio Inc

Housey Pharmaceutical Research Laboratories LLC

Ilyang Pharmaceutical Co Ltd

ImmunityBio Inc

ImmunoForge Co Ltd

ImmunoGen Inc

Incysus Therapeutics Inc

Incyte Corp

Inhibikase Therapeutics Inc

Johnson & Johnson

Juno Therapeutics Inc

LG Chem Ltd

MAA Laboratories Inc

Magenta Therapeutics Inc

Mana Therapeutics Inc

MedPacto Inc

Millennium Pharmaceuticals Inc

Nanjing Sanhome Pharmaceutical Co Ltd

Nemucore Medical Innovations Inc

Neovia Oncology Inc

Nohla Therapeutics Inc

Novartis AG

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

PharmaEssentia Corp

Prescient Therapeutics Ltd

PRISM Pharma Co Ltd

PYCTX Ltd

Shenogen Pharma Group Ltd

Shouyao Holding Co Ltd

SignalChem Lifesciences Corp

Stemline Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

Synactix Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Terns Pharmaceuticals Inc

TheraPharm Deutschland GmbH

Xencor Inc

Xspray Pharma AB

Table of Contents

Table of Contents

Introduction

Respiratory Syncytial Virus (RSV) Infections - Overview

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment

Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections - Drug Profiles

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products

Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by AbbVie Inc, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Agios Pharmaceuticals Inc, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Arromax Pharmatech Co Ltd, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Ascentage Pharma Group International, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Astex Pharmaceuticals Inc, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by AstraZeneca Plc, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Atara Biotherapeutics Inc, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by AUM Biosciences Pte Ltd, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..2), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..3), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..4), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..5), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H1 2020 (Contd..6), H1 2020

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports